Genetic characterization and therapeutic targeting of MYC-rearranged T cell acute lymphoblastic leukaemia. Read more about Genetic characterization and therapeutic targeting of MYC-rearranged T cell acute lymphoblastic leukaemia.
Unifying the diagnosis of isolated central nervous system relapse in acute lymphoblastic leukaemia based on minimal residual disease testing. Read more about Unifying the diagnosis of isolated central nervous system relapse in acute lymphoblastic leukaemia based on minimal residual disease testing.
Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. Read more about Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. Read more about A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Read more about Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.
Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Read more about Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival.
Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemia. Read more about Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemia.
Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS. Read more about Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons. Read more about Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons.
Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia. Read more about Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia.
